Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Liver Diseases and Immunity, and Hepatitis C virus research.
Biodegradable Carbonate Nanogels Loaded with Anti MFAP‐5 siRNA for Anti‐stromal Therapy of Hepatocellular Carcinoma
Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (<scp>MASLD</scp>) and Metabolic Dysfunction‐Associated Steatohepatitis (<scp>MASH</scp>): From the Growing Prevalence to Payors' Perspective
Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis
Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990–2021
Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom
Global Burden of Major Chronic Liver Diseases in 2021
Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of <scp>MASLD</scp>
The People-First Liver Charter
A European Survey to Identify Challenges in the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Incidence of Retinal Vein Occlusion and Its Association with Mortality
Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
Limitations of Guideline‐Recommended Risk Stratification in Identifying <scp>MASLD</scp> Patients for Novel Drug Treatments
Curcumin and Its Derivatives in Hepatology: Therapeutic Potential and Advances in Nanoparticle Formulations
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study
Incidence of Major Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population
Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort
Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD
Collagen turnover biomarkers to predict outcome of patients with biliary cancer
Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease
Multicompartment Polyion Complex Micelles Based on Triblock Polypept(o)ides Mediate Efficient siRNA Delivery to Cancer‐Associated Fibroblasts for Antistromal Therapy of Hepatocellular Carcinoma